Karen Tsai

Cooley advised Tenable Holdings (Nasdaq: TENB), the exposure management company exposing and closing the cybersecurity gaps that erode business value, on its definitive agreement to acquire Vulcan Cyber, an innovator in exposure management, for $150 million in enterprise value.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.

Cooley advised Battery Ventures, a global, technology-focused investment firm, on its strategic, majority growth investment in QSR Automations, a global leader in restaurant technology.